Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Equity Ratio (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Equity Ratio for 11 consecutive years, with 0.78 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 1.91% to 0.78 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.78 through Dec 2025, up 1.91% year-over-year, with the annual reading at 0.78 for FY2025, 1.91% up from the prior year.
  • Equity Ratio hit 0.78 in Q4 2025 for Voyager Therapeutics, up from 0.76 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.78 in Q4 2025 to a low of 0.32 in Q2 2022.
  • Historically, Equity Ratio has averaged 0.61 across 5 years, with a median of 0.64 in 2023.
  • Biggest five-year swings in Equity Ratio: skyrocketed 131.77% in 2021 and later plummeted 40.89% in 2022.
  • Year by year, Equity Ratio stood at 0.49 in 2021, then decreased by 24.47% to 0.37 in 2022, then surged by 81.64% to 0.67 in 2023, then increased by 13.37% to 0.76 in 2024, then increased by 1.91% to 0.78 in 2025.
  • Business Quant data shows Equity Ratio for VYGR at 0.78 in Q4 2025, 0.76 in Q3 2025, and 0.76 in Q2 2025.